FCF YoY
-5.88%
OCF YoY
+9.33%
Capex YoY
+52.51%
FCF Conversion Δ
-10.3 pp
Free cash flow bridge for AstraZeneca (AZN) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: −$569.49M
FCF bridge breakdown for AstraZeneca (AZN) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | $9.68B | — |
| Operating Cash Flow | $1.22B | +214.4% |
| Capital Expenditure | −$1.79B | -314.4% |
| Free Cash Flow | $9.11B | — |
- Prior Free Cash Flow$9.68B
- Operating Cash Flow$1.22B
- Capital Expenditure−$1.79B
- Free Cash Flow$9.11B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement